Nicole Doria-Rose
#172,813
Most Influential Person Now
American biologist
Nicole Doria-Rose's AcademicInfluence.com Rankings
Nicole Doria-Rosebiology Degrees
Biology
#14478
World Rank
#18238
Historical Rank
#2857
USA Rank
Molecular Biology
#2548
World Rank
#2589
Historical Rank
#278
USA Rank
Download Badge
Biology
Nicole Doria-Rose's Degrees
- PhD Biomedical Sciences Stanford University
- Masters Molecular Biology University of California, Berkeley
Why Is Nicole Doria-Rose Influential?
(Suggest an Edit or Addition)According to Wikipedia, Nicole Amy Doria-Rose is an American biologist. She is chief of the humoral immunology core at the Vaccine Research Center. She develops and applies assays to evaluate HIV-1 specific antibody responses during natural infection and after immunization.
Nicole Doria-Rose's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) (2366)
- Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 (2010) (1653)
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (2020) (1020)
- SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness (2020) (846)
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates (2020) (809)
- Broad and potent neutralization of HIV-1 by a gp41-specific human antibody (2012) (804)
- Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing (2011) (730)
- Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies (2014) (675)
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (2020) (613)
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 (2021) (505)
- Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface (2014) (416)
- Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies (2008) (348)
- Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. (2016) (344)
- Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody (2016) (329)
- Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables (2009) (326)
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) (322)
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) (322)
- Crystal structure, conformational fixation, and entry-related interactions of mature ligand-free HIV-1 Env (2015) (305)
- Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. (2016) (276)
- Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 (2013) (267)
- Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors (2015) (260)
- Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody (2016) (260)
- Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo (2014) (243)
- Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques (2017) (216)
- Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization (2013) (210)
- Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 (2018) (208)
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination (2022) (202)
- Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies (2015) (190)
- New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency (2015) (187)
- Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires (2016) (173)
- Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design (2015) (152)
- Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. (2017) (148)
- Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site (2015) (140)
- Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants (2021) (133)
- SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness (2020) (128)
- DNA vaccine strategies: candidates for immune modulation and immunization regimens. (2003) (128)
- Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope (2005) (117)
- Isolation of human monoclonal antibodies from peripheral blood B cells (2013) (117)
- Sequential Immunization with a Subtype B HIV-1 Envelope Quasispecies Partially Mimics the In Vivo Development of Neutralizing Antibodies (2011) (103)
- Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4+ T Cells Is Directly Associated with the Magnitude of Surface IgG Binding (2012) (101)
- mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron (2022) (98)
- Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge (2003) (97)
- Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site (2012) (90)
- Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge (2017) (90)
- Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability (2019) (84)
- Comprehensive analysis of unique cases with extraordinary control over HIV replication. (2012) (83)
- A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies (2012) (82)
- Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization (2019) (78)
- HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes (2012) (73)
- HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design (2019) (72)
- Strategies to guide the antibody affinity maturation process. (2015) (71)
- Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques (2006) (70)
- Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope (2019) (69)
- Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity (2017) (67)
- Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization (2021) (66)
- mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron (2022) (65)
- Virus‐like Particles Identify an HIV V1V2 Apex‐Binding Neutralizing Antibody that Lacks a Protruding Loop (2017) (64)
- Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains (2013) (62)
- Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates (2021) (62)
- Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. (2019) (60)
- HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins (2012) (60)
- Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity (2018) (59)
- Defining the risk of SARS-CoV-2 variants on immune protection (2022) (58)
- Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting (2017) (58)
- Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody (2015) (56)
- A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. (2019) (55)
- Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. (2018) (54)
- Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation (2019) (52)
- Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. (2019) (50)
- Longitudinal Analysis Reveals Early Development of Three MPER‐Directed Neutralizing Antibody Lineages from an HIV‐1‐Infected Individual (2019) (49)
- Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects (2021) (48)
- Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. (2019) (45)
- Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung (2021) (43)
- Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody (2018) (42)
- Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6 (2013) (42)
- Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor (2020) (40)
- Co-Immunization with Multimeric Scaffolds and DNA Rapidly Induces Potent Autologous HIV-1 Neutralizing Antibodies and CD8+ T Cells (2012) (40)
- In Vivo Selection of Rous Sarcoma Virus Mutants with Randomized Sequences in the Packaging Signal (1998) (40)
- HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies (2019) (39)
- Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects (2021) (38)
- Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth (2020) (37)
- Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. (2020) (37)
- Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry (2019) (36)
- Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants (2021) (35)
- Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice (2022) (33)
- HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design (2019) (33)
- Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen (2020) (30)
- Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. (2016) (29)
- Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants (2021) (29)
- Design of epitope-specific probes for sera analysis and antibody isolation (2012) (29)
- Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting (2019) (29)
- Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies (2017) (27)
- Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding (2016) (27)
- Antibody-secreting B cells in HIV infection (2009) (27)
- Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry (2019) (27)
- HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells. (2010) (26)
- Cytotoxic Capacity of SIV-Specific CD8+ T Cells against Primary Autologous Targets Correlates with Immune Control in SIV-Infected Rhesus Macaques (2013) (24)
- Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. (2021) (23)
- HIV neutralizing antibodies: clinical correlates and implications for vaccines. (2010) (23)
- Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. (2021) (22)
- Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates (2018) (20)
- Multigene DNA prime‐boost vaccines for SHIV89.6P (2003) (18)
- 147 Rational Design of Envelope Surface Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 (2011) (17)
- Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation (2018) (15)
- High throughput HIV-1 microneutralization assay (2013) (15)
- Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. (2019) (15)
- VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. (2020) (14)
- Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes (2019) (14)
- Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound (2020) (14)
- B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. (2021) (13)
- HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates (2017) (13)
- Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses (2020) (13)
- Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial (2022) (12)
- Coevolution of HIV-1 and broadly neutralizing antibodies. (2019) (12)
- Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation (2018) (12)
- Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. (2022) (11)
- Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant (2022) (11)
- Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody (2021) (11)
- Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway (2021) (10)
- Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. (2020) (10)
- Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals. (2019) (10)
- Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation (2018) (10)
- Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates (2021) (9)
- Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs (2018) (9)
- Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults (2022) (7)
- AIDS Vaccine 2005. (2005) (7)
- Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations (2021) (5)
- Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection (2018) (5)
- A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention (2021) (4)
- Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies (2020) (4)
- Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency (2022) (3)
- HIV Immunology Goes Out On a Limb. (2016) (3)
- Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base (2021) (3)
- Toll-like receptor 7-adapter complex modulates interferon-α production in HIV-stimulated plasmacytoid dendritic cells (2019) (3)
- Longitudinal antibody responses in people who inject drugs infected with similar HIV strains. (2020) (2)
- Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies (2021) (2)
- HIV-1 gp120–CD4-Induced Antibody Complex Elicits CD4 Binding Site–Specific Antibody Response in Mice (2020) (2)
- Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site. (2022) (2)
- Structure of Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition (2019) (2)
- Structural survey of HIV-1-neutralizing antibodies targeting Env trimer delineates epitope categories and suggests vaccine templates (2018) (2)
- Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis (2022) (2)
- Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces (2021) (2)
- A diverse collection of B cells responded to HIV infection in infant BG505 (2021) (2)
- Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants. (2022) (1)
- Binding and Neutralizing Antibody Responses to SARS-CoV-2 in Infants and Young Children Exceed Those in Adults (2021) (1)
- HIV-1 neutralizing antibodies display dual specificity for the primary and coreceptor binding sites and preferential recognition of fully-cleaved Env (2012) (1)
- Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. (2023) (1)
- Vaccination Induces Maturation of Diverse Unmutated VRC01-Class Precursors to HIV-1 Broadly Neutralizing Antibodies in an Ig-Humanized Mouse Model (2020) (1)
- Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2 (2022) (1)
- Analytical characterization of broadly neutralizing antibody CAP256LS heavy chain clipping during manufacturing development (2022) (1)
- Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life (2022) (1)
- Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial (2022) (1)
- Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen (2020) (0)
- Structural comparison of somatically related PG9 and PG16 in complex with their epitope reveals differences in glycan recognition (2012) (0)
- B-111 Sulfotyrosine-mediated V2-V3 interaction stabilizes the HIV-1 envelope trimer facilitating immune evasion (2016) (0)
- Rhesus macaque Bcl-6/Bcl-xL B cell immortalization: Discovery of HIV-1 neutralizing antibodies from lymph node. (2023) (0)
- Crystal structure of VRC46.01 Fab in complex with gp41 peptide (2019) (0)
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness (2020) (0)
- A1 The role of virus-antibody co-evolution in the development of a V3-glycan-directed HIV-1 broadly neutralizing antibody lineage (2019) (0)
- Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor (2020) (0)
- Limited anti-HIV neutralizing antibody breadth and potency before and after HIV superinfection in Danish men who have sex with men (2018) (0)
- Variable Dependence on Glycan Recognition within a Lineage of V1V2-directed HIV Neutralizing Antibodies (2014) (0)
- A meta-analysis of passive immunization studies shows an association of serum neutralizing antibody titer with protection against SHIV challenge (2019) (0)
- Crystal structure of VRC43.01 Fab (2019) (0)
- Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice (2022) (0)
- Augmenting Neutralization breadth against Diverse HIV-1 by increasing the Ab-Ag interface on V2 (2021) (0)
- Isolation of broadly neutralizing HIV-1 antibodies from high-throughput single B cell culture (2012) (0)
- Potent vaccine sera target epitopes that overlap the CD4 binding site. (2015) (0)
- Progress in vaccine development for infectious diseases-a Keystone Symposia report. (2023) (0)
- Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography (2021) (0)
- Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 (2018) (0)
- Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. (2023) (0)
- P05-10. Sequential immunization with a subtype B HIV-1 envelope quasispecies elicits broader neutralization than vaccination with a single envelope clone (2009) (0)
- Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones (2022) (0)
- Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency (2023) (0)
- A Structure-Based Matrix Approach Yields Improved VRC01-Class Antibodies for HIV-1 Therapy and Prevention (2020) (0)
- Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1 (2022) (0)
- Vaccine-elicited cross-neutralizing HIV antibodies directed to multiple sites of Env vulnerability following heterologous NFL trimer-liposome prime:boosting (2019) (0)
- Crystal structure of VRC42.04 Fab in complex with gp41 peptide (2019) (0)
- Serum recognition of the native trimer and effects of a key mutation in the CD4 binding loop. (2015) (0)
- Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2 (2022) (0)
- Overview of human plasmas and animal sera. (2015) (0)
- HIV-Specific Antibodies Mediate Rapid Antibody-Dependent Cellular Cytotoxicity Against Primary HIV-Infected CD4+T Cells (2010) (0)
- Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity (2018) (0)
- Crystal structure of human Fab CAP256-VRC26.25, a potent V1V2-directed HIV-1 broadly neutralizing antibody (2014) (0)
- Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation (2018) (0)
- Molecular Dissection Of Human Antibody Responses Following Prefusion-Stabilized RSV F Vaccination (2020) (0)
- Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization (2023) (0)
- Potent Anti-Viral Activity of a Trispecific HIV Antibody in SHIV-Infected Monkeys (2021) (0)
- Crystal structure of VRC43.03 Fab (2019) (0)
- AIDS vaccine 2005. 6-9 September 2005, Montreal, Canada (2005) (0)
- Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones (2022) (0)
- Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4 (2022) (0)
- Crystal structure of VRC42.01 Fab in complex with T117-F MPER scaffold (2019) (0)
- , In Vivo Infection Improves Protection against Lentiviral In Vitro Neutralizing HIV-1 Antibody Enhanced Potency of a Broadly (2014) (0)
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness Preview (2020) (0)
- HIV-1 V 1 V 2 antibody with exceptional potency 5 6 (2015) (0)
- P-C17 Critical role of V2 Sulfotyrosines in Stabilizing the HIV-1 Envelope Trimer in its Closed, Antibody-Protected Conformation (2017) (0)
- 126 Broadly Neutralizing HIV Abs: Gains and Losses in Translation (2012) (0)
- Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge (2004) (0)
- Isolation and Characterization of Cross-Neutralizing COVID-19+ Subjects (2021) (0)
This paper list is powered by the following services:
Other Resources About Nicole Doria-Rose
What Schools Are Affiliated With Nicole Doria-Rose?
Nicole Doria-Rose is affiliated with the following schools:
